Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
NCT Number: NCT05198089
The purpose of this study is to pilot a beta version of a digital resource that supports the religious and spiritual beliefs of cancer patients, "MyInspiration".After receiving a cancer diagnosis, survivors are encouraged to make major life-altering decisions related to their treatment and care. The availability of spiritual/religious resources during cancer treatment may positively impact patient outcomes, feelings of well-being, and be essential components of holistic, patient-centered care. MyInspiration is a digital tool focused on spiritual and/or religious guidance and support that can be customized based on patient preferences and administered to cancer patients and their family members during cancer treatment. MyInspiration may help improve spiritual well-being in patients with cancer.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Columbus, Ohio, 43210, United States
PRIMARY OBJECTIVES:
I. Conduct a pilot of MyInspiration to determine acceptability, feasibility, and general satisfaction by its end-users.
II. Explore the qualitative opinions of patients who participated in the feasibility trial more in-depth using 1-on-1 interviews.
OUTLINE: Single-group feasibility pilot.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Use MyInspiration website
Time frame: Up to 30 days
Feasibility will be assessed by ratio of patients that enroll of the patients that indicate interest in the study
Time frame: Up to 30 days
Feasibility will be assessed by completion rates of both the baseline and follow-up measures
Time frame: Up to 30 days
Feasibility will be assessed by meta-analytics of website usage.
Time frame: Up to 30 days
Acceptability will be assessed by study attrition rates.
Time frame: Up to 30 days
General Satisfaction will be assessed using an investigator-created 6-item scale assessing participants experience with MyInspo overall and its specific components
Time frame: Up to 30 days
Decisional regret will be assessed post cancer-directed surgery using The Decisional Regret Scale.Items will also be adapted from scales developed by Clark et al. regarding the perceptions of one's treatment decisions, their outcomes, and the inherent uncertainty of decision making and cancer control.
Time frame: Up to 30 days
Spiritual well-being will be assessed using the Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being, the Meaning of Cancer Subscale from the Impact of Cancer scale, and 1-item assessing spiritual distress. The Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being is a 12-item scale with a minimum score of 0 and a maximum score of 48; higher scores indicate a greater sense of spiritual well-being.
Ohio State University Comprehensive Cancer Center
Other
The Development and Pilot of MyInSPO: an Individualized Spirituality Program for Oncology Patients to Improve Spiritual Well-Being
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03223753
Carcinoma, Carcinoma in Situ
Birmingham, Alabama, United States
View Trial DetailsNCT06442891
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Ann Arbor, Michigan, United States
View Trial DetailsNCT06602999
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
San Francisco, California, United States
View Trial DetailsNCT06484595
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Seattle, Washington, United States
View Trial Details